Prospective, randomized, multicenter clinical study comparing a self-expanding covered stent to percutaneous transluminal angioplasty for treatment of upper extremity hemodialysis arteriovenous fistula stenosis.

Use of a covered stent after percutaneous transluminal angioplasty (PTA) was compared to PTA alone for treatment of upper extremity hemodialysis patients with arteriovenous fistula (AVF) stenoses. Patients with AVF stenosis of 50% or more and evidence of AVF dysfunction underwent treatment with PTA followed by randomization of 142 patients to include a covered stent or 138 patients with PTA alone. Primary outcomes were 30-day safety, powered for noninferiority, and six-month target lesion primary patency (TLPP), powered to test whether TLPP after covered-stent placement was superior to PTA alone.

Urgent-start peritoneal dialysis results in fewer procedures than hemodialysis.

Background: Peritoneal dialysis (PD) is an underutilized modality for hospitalized patients with an urgent need to start renal replacement therapy in the USA. Most patients begin hemodialysis (HD) with a tunneled central venous catheter (CVC).

Methods: We examined the long-term burden of dialysis modality-related access procedures with urgent-start PD and urgent-start HD in a retrospective cohort of 73 adults.

Cause for inadequate clearance: hemodialysis catheter migration into the coronary sinus.

Complications associated with central dialysis catheters prove to be an important source of morbidity that challenge patients and clinicians alike. While thrombosis, stenosis, and infection remain the most common threats to functioning central dialysis catheters, malposition of such devices may similarly result in serious consequences. Despite advanced techniques used to confirm initial catheter placement, the very nature of these catheters entails frequent manipulation for vascular access and therefore they may migrate after repeated use.

Nickel contact hypersensitivity in children.

Nickel allergic contact dermatitis is the most prevalent allergy in North America, with an incidence of 14.3%. It is on the rise from 10 years ago, when the incidence was 10%.